Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells

Sanfelice, Raquel Arruda; Machado, Laís Fernanda; Bosqui, Larissa Rodrigues; Miranda-Sapla, Milena Menegazzo; Tomiotto-Pellissier, Fernanda; Dalevedo, Gabriela de Alcântara; Ioris, Dielle; Reis, Guilherme Fonseca; Panagio, Luciano Aparecido; Navarro, Italmar Teodorico; Bordignon, Juliano; Conchon‐Costa, Ivete; Pavanelli, Wander Rogério; Almeida, Ricardo Sérgio; Costa, Idessânia Nazareth

doi:10.1016/j.exppara.2017.07.009

Cited by 12 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are similar to Sanfelice et al . (2017 b ), who demonstrated the in vitro anti-proliferative effect of rosuvastatin against T. gondii tachyzoites (RH strain). In that study, the authors observed a 37 and 27% reduction in the number of infected cells after 50 and 25 mg mL −1 of rosuvastatin treatment, respectively, when compared with the negative control.…”

Section: Discussionmentioning

confidence: 99%

“…Identifying drugs with anti-bradyzoites effects, effective in the chronic phase, is a great challenge to researchers. Intriguingly, in vitro and in vivo studies showed that statins, a class of lipid-lowering medications, can reduce T. gondii replication (Li et al, 2013(Li et al, , 2017Sanfelice et al, 2017aSanfelice et al, , 2018, especially rosuvastatin (Sanfelice et al, 2017b). Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in humans, but studies suggest that statins can also negatively influence T. gondii isoprenoids biosynthesis (Li et al, 2013(Li et al, , 2017.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain

et al. 2019

View full text Add to dashboard Cite

This study evaluated the effects of rosuvastatin in vivo on toxoplasmosis chronic infection. Thirty-five Swiss mice were orally infected (ME-49 strain). After 50 days, the mice were separated into five groups: GI – non-infected, GII – infected, GIII – infected and treated with pyrimethamine and sulfadiazine (12.5 + 50 mg kg−1 body weight day−1), GIV and GV – infected and treated with rosuvastatin 10 and 40 mg kg−1 body weight day−1, respectively. After 21 days, we collected blood, liver, lungs, femoral biceps and brain were removed for Toxoplasma gondii DNA quantification by qPCR and histopathological analysis. GIV and GV did not present premature death or clinical changes, and the hepatic enzyme levels were lower compared to GI. Toxoplasma gondii DNA was detected mainly in brain and muscle, but the parasite load was significantly lower in GV compared to GII brains (P < 0.05). Histopathological changes were observed in brains, with T. gondii cysts as well as an inflammatory condition, including necrosis areas in GII and GIII. These data confirm active infection with tissue injury. This inflammatory condition was attenuated in the groups treated with rosuvastatin, especially R40 (GV). Our findings demonstrated the in vivo action of rosuvastatin in reducing cerebral parasitic load and indicate that this drug may interfere in chronic toxoplasmosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain

et al. 2019

View full text Add to dashboard Cite

show abstract

“…All (Almeida et al, 2017). The M. oleifera species was deposited in the herbarium of Federal University of Sergipe, no.…”

Section: Toxoplasma Gondii Rh Strainmentioning

confidence: 99%

“…The percentages of infection and intracellular proliferation inhibition rates of T. gondii were calculated as: average of the infection or intracellular proliferation rate analysed in untreated cells, corresponding to 100% infection or intracellular proliferation rate. The percentages of inhibition of these parameters submitted to treatments with M. oleifera were calculated by subtracting the percentage values obtained for treated cells from those obtained for untreated cells (Sanfelice et al, 2017).…”

Section: Anti-t Gondii Activity Assay In Vitromentioning

confidence: 99%

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…This agreed with Cho et al (2019) who reported that rosuvastatin markedly reduced cerebral parasitic load and interfered with the chronic toxoplasmosis. Previously, Sanfelice et al (2017) reported that the activity of rosuvastatin in HeLa cells infected with T. gondii caused a significant reduction in number of infected cells and the proliferation index of the intracellular parasite as compared with the conventional toxoplasmosis treatment (pyrimethamine, sulfadiazine and folic acid). Nevertheless, the brain pathological alterations were attenuated in the rosuvastatin treated mice, which showed more intense glial cell proliferation and gliosis area, indicating tissue repair.…”

Section: Discussionmentioning

confidence: 99%

In Vivo Assessment of Rosuvastatin Efficacy on Experimental Murine With Avirulent Toxoplasmosis

Omar

ALI

ELFKHANY

et al. 2022

Journal of the Egyptian Society of Parasitology

View full text Add to dashboard Cite

Toxoplasmosis is a contagious illness that is brought on by the parasite Toxoplasma gondii. The strain of Toxoplasma gondii may have an effect on how severe the symptoms of toxoplasmosis are. Immunocompromised people are more likely to develop neurological, ocular, and systemic diseases as a result of toxoplasmosis. Rosuvastatin ® is one of the promising drugs in the treatment of toxoplasmosis. This study determined the rosuvastatin efficacy in treating murine toxoplasmosis. This is being done in an effort to make up for the deficiencies that are present in other standard medications. Mice were divided into 7 groups of 10 mice each. GI: Neither infected nor treated (normal control). GII: Infected, non-treated mice (positive control). GIII: Mice given Spiramycin ® as prophylaxis before infection. GIV: Mice given rosuvastatin as prophylaxis before infection. GV: Mice infected and treated by spiramycin after 6 th week for 2 weeks. GVI: Mice infected and treated by rosuvastatin after 6 th week for 2 weeks. GVII: Following the sixth week, infection was confirmed, and treatment consisted of a combination of rosuvastatin and spiramycin for two weeks. Histological examination of brain and liver, and counting brain cysts, were used to evaluate the efficacy of treatment.The results showed that rosuvastatin treated group showed significant reduction in brain cysts and improved histopathological picture in brain and liver tissue. Combination of rosuvastatin and spiramycin gave the best results in reduction of brain cysts number and the least pathological changes in brain and liver tissue. The effect of rosuvastatin was augmented after combination with spiramycin.

show abstract

Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells

Cited by 12 publications

References 42 publications

Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain

Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

In Vivo Assessment of Rosuvastatin Efficacy on Experimental Murine With Avirulent Toxoplasmosis

Contact Info

Product

Resources

About